Physician profile
Ayush Singh
NPI 1447773676
$2,010.30
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.89 · 2020: $43.51 · 2021: $26.01 · 2022: $232 · 2023: $770 · 2024: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.30 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $223.38 | 2020-2024 | |
| Mdd US Operations, LLC | $212.92 | 2024 | Gocovri |
| Biogen, INC. | $184.37 | 2022-2024 | Tysabri, Vumerity, Avonex |
| Celgene Corporation | $131.44 | 2022-2024 | Zeposia |
| Ucb, INC. | $126.53 | 2023-2024 | Briviact, Rystiggo |
| Abbvie INC. | $111.68 | 2023-2024 | Botox, Qulipta |
| Sumitomo Pharma America, INC. | $100.42 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $100.00 | 2024 | Ultomiris |
| Genentech USA, INC. | $73.95 | 2023-2024 | Evrysdi, Ocrevus, Enspryng |
| Argenx US, INC. | $60.76 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $58.59 | 2022-2023 | |
| Csl Behring | $57.83 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.00 | 2022 | |
| Eisai INC. | $49.82 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $45.39 | 2023 | Austedo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.73 | 2022-2024 | Amyvid |
| Neurelis, INC. | $35.56 | 2024 | Valtoco |
| Corium, LLC | $35.09 | 2022-2023 | Adlarity |
| Neurocrine Biosciences, INC. | $34.73 | 2022-2024 | Ingrezza |
| Sk Life Science, INC. | $32.26 | 2024 | |
| Amgen INC. | $31.18 | 2022-2023 | Aimovig |
| Acadia Pharmaceuticals INC | $31.03 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $28.93 | 2023 | Rexulti |
| Amneal Pharmaceuticals LLC | $26.22 | 2023 | Rytary |
| Microtransponder, INC. | $22.35 | 2024 | |
| Sunovion Pharmaceuticals INC. | $21.92 | 2022 | |
| Lundbeck LLC | $18.97 | 2022 | |
| Cala Health, INC. | $17.25 | 2023 | Cala Trio |
| Upsher-Smith Laboratories LLC | $16.23 | 2022 | |
| Medtronic USA, INC. | $14.89 | 2019 | |
| Si-Bone, INC. | $13.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayush Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.